Reimagine Care — acquired by Cureety

Reimagine CareReported

Acquisition

acquired by Cureety

Cureety acquires AI virtual oncology company Reimagine Care.

Buyer
Cureety
Value
undisclosed

Cureety, a company operating in the oncology sector, has announced its acquisition of Reimagine Care. This strategic move, completed on September 2, 2026, aims to integrate Reimagine Care’s AI-driven virtual oncology capabilities into Cureety’s existing offerings, signaling a continued trend towards technology-enhanced cancer care solutions.

The deal

On September 2, 2026, Cureety acquired Reimagine Care. While the specific financial terms of the acquisition have not been disclosed, the transaction highlights a focus on leveraging artificial intelligence to advance precision oncology. This acquisition is categorized as an acquisition within the Health AI Deal Tracker directory.

Who the company is

Reimagine Care operates as an AI-driven virtual oncology company. Its core offering centers on utilizing artificial intelligence to support cancer care, likely through virtual platforms and data-driven insights. While the exact details of its product suite are not fully elaborated in the provided information, the emphasis on “virtual oncology” suggests solutions that extend beyond traditional in-person clinical settings, potentially encompassing remote monitoring, personalized treatment pathways, or AI-assisted decision support for clinicians. The company’s focus on oncology indicates a specialization in addressing the complex needs of cancer patients and their care teams.

Why the buyer (or public listing) cares

Cureety’s acquisition of Reimagine Care underscores a strategic interest in strengthening its position within the precision oncology landscape through AI integration. By incorporating Reimagine Care’s AI-driven virtual oncology platform, Cureety is likely aiming to enhance its ability to deliver more personalized and efficient cancer treatments. The move suggests a desire to expand capabilities in areas such as patient management, treatment optimization, and potentially remote care delivery, all powered by artificial intelligence. This acquisition could allow Cureety to offer a more comprehensive suite of services to its customers, potentially improving patient outcomes and streamlining clinical workflows by leveraging advanced AI technologies for more precise and tailored care.

What this means for health AI

This acquisition reflects a broader trend within the health AI sector: the increasing integration of artificial intelligence into specialized medical fields, particularly oncology. The focus on AI-driven precision oncology highlights the growing recognition of AI’s potential to analyze complex patient data, identify optimal treatment strategies, and support personalized care plans. Virtual oncology, as a segment, is also gaining traction, indicating a shift towards more accessible and digitally-enabled cancer care models. Deals like this suggest that companies are actively seeking to consolidate AI capabilities to offer more comprehensive and integrated solutions. The undisclosed value of the deal, while common in private acquisitions, points to a dynamic market where strategic fit and technological synergy are key drivers. This transaction further solidifies the role of AI as a critical component in the evolution of cancer treatment and management.

This record aggregates public sources. Confirm figures with the linked originals before you rely on them.
Share
Was this article helpful?